Type1 Interferons Potential Initiating Factors Linking Skin Wounds With Psoriasis Pathogenesis

Area of Science:

• Immunology
• Dermatology
• Autoimmunity

Background:

• Psoriasis is a chronic autoimmune skin disease often triggered by skin injury (Koebner phenomenon).
• Type 1 interferons (IFNα, IFNβ) are implicated in initiating psoriasis post-injury, with a known IFN-inducible gene signature in psoriatic skin.
• IFN treatments can exacerbate psoriasis, while blocking IFN signaling inhibits inflammation in animal models.

Purpose of the Study:

• To review the mechanisms by which skin injury induces type 1 interferons (IFNs).
• To explore how these IFNs initiate autoimmune cascades leading to psoriasis.
• To discuss potential therapeutic strategies targeting keratinocytes and IFNs for autoimmune skin diseases.

Main Methods:

• Review of existing literature on psoriasis pathogenesis, type 1 interferons, and skin injury response.
• Analysis of the roles of epidermal keratinocytes (KCs) and plasmacytoid dendritic cells (pDCs) in IFN production.
• Examination of the LL37 peptide's role in potentiating immune pathways.

Main Results:

• Skin injury rapidly induces IFNβ from KCs and IFNα from pDCs via distinct pathways.
• The antimicrobial peptide LL37 enhances dsRNA pathways in KCs and RNA/DNA pathways in pDCs, driving type 1 IFN production.
• KC-derived IFNβ promotes dendritic cell maturation and T cell proliferation, contributing to autoimmune activation.

Conclusions:

• Skin injury-induced type 1 IFNs play a critical role in initiating autoimmune responses and psoriasis pathogenesis.
• Targeting keratinocytes and type 1 IFNs, potentially combined with T cell therapy, could offer sustainable treatments for psoriasis.
• Understanding the dsRNA immune pathway's role is crucial for developing effective therapies for auto-inflammatory skin conditions.